Invitae Reports $53.5 Million in Quarterly Revenue Driven by More Than 111,000 Samples in Quarterly Volume
SAN FRANCISCO, Aug. 6, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the second quarter ended June 30, 2019.
"We have now delivered our 25th quarter of impressive growth in both revenue and volume, while continuing to invest in new technologies that further our position as a leader in the rapidly evolving genetics industry," said Sean George, co-founder and chief executive officer of Invitae. "We are beginning to stand out to our customers as the company that offers the most comprehensive menu of high-quality, affordable genetic testing to everyone who can benefit, enabling us to bring genetics more broadly into mainstream medicine. With the success we've had in the first half of the year, we are confident in our ability to achieve our 2019 guidance."
Second Quarter 2019 Financial Results
-- Accessioned more than 111,000 samples in the second quarter of 2019,
representing a 52% increase over the more than 73,000 samples in the
second quarter of 2018. Billable volume was nearly 111,000 in the second
quarter of 2019
-- Generated revenue of $53.5 million in the second quarter of 2019,
representing a 43% increase over the second quarter of 2018 revenue of
$37.3 million
-- Reported the average cost per sample at $252 in the second quarter of
2019, representing a 10% reduction from a $279 average cost per sample
in the second quarter of 2018
-- Achieved gross profit of $25.5 million in the second quarter of 2019
compared to $16.9 million in gross profit in the second quarter of 2018
Total operating expenses, which exclude cost of revenue, for the second quarter of 2019 were $77.4 million, which includes $25.3 million in research and development, $21.3 million in general and administrative and $30.8 million in sales and marketing expenses for the quarter. Comparatively, total operating expenses for the second quarter of 2018 was $46.9 million. Contributing to the increase in operating expense was acquisition-related costs.
For the second quarter of 2019, Invitae reported a net loss of $48.7 million, or a $0.54 loss per share, compared to a net loss of $31.7 million in the second quarter of 2018, or a $0.47 net loss per share. Excluding acquisition-related expenses and income tax benefit, our non-GAAP net loss was $46.8 million in the second quarter of 2019, or a $0.52 non-GAAP net loss per share.
As of June 30, 2019, cash, cash equivalents, restricted cash, and marketable securities totaled $254.0 million. Net decrease in cash, cash equivalents and restricted cash for the quarter was $5.1 million. Cash burn for the quarter was $33.2 million.
Invitae's Corporate and Scientific Highlights
-- Reduced patient-pay pricing for its non-invasive prenatal screening
(NIPS) to $99, increasing access to testing for women in early pregnancy
-- Announced the addition of supplemental RNA testing for variants of
uncertain significance (VUS), beginning with patients undergoing cancer
testing, to contribute to research and further reduce the uncertainty
inherent in genetic testing results
-- Launched Invitae's direct channel to make it easier for customers to
order and receive the same high-quality, medical genetic testing from
Invitae that experts use and trust
-- Continued progress with payers, as Invitae was named one of seven labs
in UnitedHealthcare's (UHC) Preferred Lab Network (PLN), effective as of
July 1, 2019j. The PLN was designed to make it easier for providers to
choose from UHC's broader network of more than 300 labs, based on a
rigorous quality review process. Services accessed through the PLN are
at a lower average cost than other lab providers
-- Presented various studies at The American College of Medical Genetics
and Genomics (ACMG) Annual Clinical Genetics Meeting generated by
researchers from Invitae
-- Shared data on the limitations of a direct-to-consumer strategy
testing that detects only three of the thousands of genetic variants
in BRCA1 and BRCA2 associated with hereditary breast and ovarian
cancer (HBOC) risk, showing this strategy results in a clinical
false negative rate of approximately 90% of those at risk for HBOC
-- Shared data from more than 113,000 patients that support broadening
genetic testing guidelines to include patients with potentially
actionable germline variants that are missed when clinicians adhere
to current guidelines
-- Presented research at the American Society of Clinical Oncology (ASCO)
Annual Meeting demonstrating the importance of germline multigene panel
testing in guiding therapy for expanding groups of cancer patients can
impact patient outcomes and inform surgical strategy, treatments, and
clinical trial eligibility
-- Continued investment in M&A to drive technologies to scale the business
and improve quality
-- Acquired Singular Bio, Inc., a privately held company developing
single molecule detection technology enabling lower costs and
expanded use of high-quality cell-free, nucleic acid analysis,
initially for application in NIPS
-- Acquired Jungla Inc., a privately held company funded by Andreessen
Horowitz (a16z) that has developed a cloud-based platform that
further enhances Invitae's genetic variant interpretation and
ability to deliver high-quality, more affordable genetic testing
-- Extended Invitae's genome network with the addition of 12 new biopharma
partnership programs in the second quarter of 2019
-- Launched ID YOUR IRD, an initiative with Spark Therapeutics, to
offer genetic testing at no charge to patients suspected by their
healthcare providers of having an inherited retinal disease (IRD), a
group of rare, progressive eye disorders that may result in vision
loss or blindness caused by inherited genetic changes
-- Announced the availability of its Detect programs to provide
no-charge genetic testing to improve diagnosis and treatment in four
conditions: muscular dystrophy, hereditary prostate cancer,
cardiomyopathy and arrhythmia and lysosomal storage diseases
-- Announced the appointment of Sean George as the new chairman of the
board of directors and the retirement of executive chairman Randy Scott,
effective September 1, 2019
"During my 35 years in the biotech industry, it has been amazing to watch the genomics field emerge from the early days of the human genome project to now affecting millions of lives around the world," said Randy Scott, executive chairman. "I couldn't be more proud to be a part of the Invitae story, and I look forward to following the progress of a great team on a great mission to make genetic information more affordable and accessible for all. I plan to continue to support the Invitae team as a private investor and look forward to the tremendous growth that lies ahead."
"Given the stage of growth we're in, we are confident in our ability to scale as we bring genetics to mainstream medicine, and Randy's leadership and vision have been central to getting us here," said Sean George. "We're deeply grateful to Randy for his passion for Invitae's success and for his role as a pioneer and innovator in the genetics industry."
Webcast and Conference Call Details
Management will host a conference call and webcast today at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss financial results and recent developments. The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 6153749. Following prepared remarks, management will respond to questions from investors and analysts, subject to time limitations.
The live webcast of the call and slide deck may be accessed by visiting the investors section of the company's website at ir.invitae.com. A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the company's website.
About Invitae
Invitae Corporation (NYSE: NVTA) is the leading advanced medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's financial results for the quarter ended June 30, 2019; estimated guidance for 2019 and future financial performance; the impact of the company's acquisitions, product offerings and distribution channels; the retirement plans of the company's executive chairman, appointment of a new chairman, and the timing thereof; and the company's beliefs regarding the growth of its business, its position and impact on the genetic testing industry, its success in executing on its mission and achieving its goals, and the benefits of genetic testing. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the actual results for the quarter ended June 30, 2019 and the year ending December 31, 2019; the company's ability to continue to grow its business; the company's history of losses; the company's ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; the company's failure to successfully integrate or fully realize the anticipated benefits of acquired businesses; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2019. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.
Non-GAAP Financial Measures
To supplement Invitae's consolidated financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP), the company is providing non-GAAP research and development expense, non-GAAP general and administrative expense, non-GAAP net loss and net loss per share, and cash burn, which are non-GAAP financial measures. These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similarly-titled measures presented by other companies. Management believes these non-GAAP financial measures are useful to investors in evaluation the company's ongoing operating results and trends.
Non-GAAP research and development expense, non-GAAP general and administrative expense and non-GAAP net loss exclude acquisition-related stock-based compensation related to inducement grants, post-combination expense related to the acceleration of equity grants in connection with the company's business combinations, and acquisition-related income tax benefits. These non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact on the reported financial results. Management accounts for this limitation by analyzing results on a GAAP basis as well as a non-GAAP basis and also by providing GAAP measures in the company's public disclosures.
Cash burn excludes (1) changes in marketable securities other than investments made in privately held companies, (2) cash received from equity financings, including proceeds from a public offering of common stock in March 2019, (3) cash received from loan proceeds, and (4) cash received from exercises of warrants. Management believes cash burn is a liquidity measure that provides useful information to management and investors about the amount of cash consumed by the operations of the business. A limitation of using this non-GAAP measure is that cash burn does not represent the total change in cash, cash equivalents, and restricted cash for the period because it excludes cash provided by or used for other operating, investing or financing activities. Management accounts for this limitation by providing information about the company's operating, investing and financing activities in the statements of cash flows in the consolidated financial statements in the company's most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K and by presenting net cash provided by (used in) operating, investing and financing activities as well as the net increase in cash, cash equivalents and restricted cash in reconciliation of cash burn.
In addition, other companies, including companies in the same industry, may not use cash burn, non-GAAP research and development and general and administrative expense, or non-GAAP net loss or may calculate these metrics in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-GAAP measures as comparative measures. Because of these limitations, the company's non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the non-GAAP reconciliations provided in the table below.
INVITAE CORPORATION
Consolidated Balance Sheets
(in thousands)
(unaudited)
June 30, December 31,
2019 2018
---
Assets
Current assets:
Cash and cash equivalents $
247,000 $
112,158
Marketable securities 800 13,727
Accounts receivable 23,143 26,296
Prepaid expenses and other
current assets 16,976 13,258
Total current assets 287,919 165,439
Property and equipment,
net 29,021 27,886
Operating lease assets 40,228
Restricted cash 6,243 6,006
Intangible assets, net 57,832 30,469
Goodwill 76,556 50,095
Other assets 5,103 3,064
Total assets $
502,902 $
282,959
Liabilities and stockholders' equity
Current liabilities:
Accounts payable $
5,255 $
7,812
Accrued liabilities 27,801 26,563
Operating lease
obligations 5,102
Finance lease obligations 1,934 1,937
Total current liabilities 40,092 36,312
Operating lease
obligations, net of
current portion 45,694
Finance lease obligations,
net of current portion 429 1,375
Debt 75,184 74,477
Other long-term
liabilities - 8,956
Total liabilities 161,399 121,120
Stockholders' equity:
Common stock 9 8
Accumulated other
comprehensive income
(loss) - (5)
Additional paid-in
capital 944,559 678,548
Accumulated deficit (603,065) (516,712)
Total stockholders' equity 341,503 161,839
Total liabilities and
stockholders' equity $
502,902 $
282,959
INVITAE CORPORATION
Consolidated Statements of Operations
(in thousands, except per share data)
(unaudited)
Three Months Ended Six Months Ended
June 30,
June 30,
2019 2018 2019 2018
Revenue:
Test revenue $
52,302 $
36,350 $
91,921 $
63,403
Other revenue 1,173 956 2,107 1,574
Total revenue 53,475 37,306 94,028 64,977
Cost of revenue 28,006 20,447 49,260 38,523
Research and development 25,302 15,784 43,296 31,150
Selling and marketing 30,779 18,707 54,972 37,631
General and administrative 21,274 12,436 34,593 24,216
Loss from operations (51,886) (30,068) (88,093) (66,543)
Other income, net 1,381 188 2,019 1,835
Interest expense (2,121) (1,791) (4,229) (3,083)
Net loss before taxes (52,626) (31,671) (90,303) (67,791)
Income tax benefit (3,950) (3,950)
Net loss $
(48,676) $
(31,671) $
(86,353) $
(67,791)
Net loss per share, basic and
diluted $
(0.54) $
(0.47) $
(1.01) $
(1.12)
Shares used in computing net loss
per share, basic and diluted 90,863 67,807 85,148 60,775
INVITAE CORPORATION
Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
Six Months Ended June 30,
2019 2018
---
Cash flows from operating activities:
Net loss $
(86,353) $
(67,791)
Adjustments to reconcile net loss to net cash used
in operating activities:
Depreciation and amortization 6,725 6,927
Stock-based compensation 19,540 10,505
Remeasurements of liabilities
associated with business
combinations (286) 709
Benefit from income taxes (3,950)
Other 1,182 462
Changes in operating assets and liabilities, net
of business acquired:
Accounts receivable 3,153 (4,037)
Prepaid expenses and other
current assets (3,825) (512)
Other assets 2,410 (1,428)
Accounts payable (3,954) (3,106)
Accrued expenses and other
liabilities 4,267 (396)
Net cash used in operating
activities (61,091) (58,667)
Cash flows from investing activities:
Purchases of marketable
securities (20,781) (900)
Proceeds from sales of
marketable securities - 19,965
Proceeds from maturities of
marketable securities 34,000 2,078
Acquisition of business, net of
cash acquired 3,193
Purchases of property and
equipment (8,824) (3,084)
Net cash provided by investing
activities 7,588 18,059
Cash flows from financing activities:
Proceeds from public offerings
of common stock, net of
issuance costs 184,490 53,480
Proceeds from issuance of common
stock 5,123 4,933
Proceeds from debt financing - 19,781
Finance lease principal payments (1,031) (1,170)
Net cash provided by financing
activities 188,582 77,024
Net increase in cash, cash
equivalents and restricted cash 135,079 36,416
Cash, cash equivalents and
restricted cash at beginning of
period 118,164 17,459
Cash, cash equivalents and
restricted cash at end of
period $
253,243 $
53,875
INVITAE CORPORATION
Reconciliation of GAAP to Non-GAAP Research and Development Expense
(in thousands)
(unaudited)
Three Months Ended Six Months Ended
June 30,
June 30,
2019 2018 2019 2018
Research and development $
25,302 $
15,784 $
43,296 $
31,150
Acquisition-related stock-
based compensation (2,586) (2,586)
Non-GAAP research and
development $
22,716 $
15,784 $
40,710 $
31,150
Reconciliation of GAAP to Non-GAAP General and Administrative Expense
(in thousands)
(unaudited)
Three Months Ended Six Months Ended
June 30,
June 30,
2019 2018 2019 2018
General and administrative $
21,274 $
12,436 $
34,593 $
24,216
Acquisition-related post-
combination expense (3,212) (3,212)
Non-GAAP general and
administrative $
18,062 $
12,436 $
31,381 $
24,216
Reconciliation of Net Loss to Non-GAAP Net Loss Per Share
(in thousands, except per share data)
(unaudited)
Three Months Ended Six Months Ended
June 30,
June 30,
2019 2018 2019 2018
Net loss $
(48,676) $
(31,671) $
(86,353) $
(67,791)
Acquisition-related stock-
based compensation 2,586 2,586
Acquisition-related post-
combination expense 3,212 3,212
Acquisition-related income tax
benefit (3,950) (3,950)
Non-GAAP net loss $
(46,828) $
(31,671) $
(84,505) $
(67,791)
Non-GAAP net loss per share,
basic and diluted $
(0.52) $
(0.47) $
(0.99) $
(1.12)
Shares used in computing net
loss per share, basic and
diluted 90,863 67,807 85,148 60,775
INVITAE CORPORATION
Reconciliation of Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash to Cash Burn
(in thousands)
(unaudited)
Three Months Three Months Six Months
Ended March Ended June Ended June 30,
31, 2019 30, 2019 2019
---
Net cash used in
operating
activities (28,366) (32,725) (61,091)
Net cash provided
by (used in)
investing
activities (17,545) 25,133 7,588
Net cash provided
by (used in)
financing
activities 186,120 2,462 188,582
Net increase
(decrease) in
cash, cash
equivalents and
restricted cash 140,209 (5,130) 135,079
Adjustments:
Purchases of
investments 20,781 20,781
Maturities of
investments (6,000) (28,000) (34,000)
Proceeds from
public offering
of common stock,
net of issuance
costs (184,490) (184,490)
Proceeds from
exercises of
warrants (88) (25) (113)
Cash burn (29,588) (33,155) (62,743)
Contact:
Laura D'Angelo
ir@invitae.com
(628) 213-3369
View original content to download multimedia:http://www.prnewswire.com/news-releases/invitae-reports-53-5-million-in-quarterly-revenue-driven-by-more-than-111-000-samples-in-quarterly-volume-300897506.html
SOURCE Invitae Corporation
